US-based non-profit organisation HudsonAlpha Institute for Biotechnology has bought Illumina's HiSeq X Ten sequencing system, which allows the company to produce and analyse genomic data faster and cheaper.
The purchase of the system is part of the Institute's commitment to research programmes for genomics excellence in patient care.
HiSeq X Ten system will be integrated into the Institute's current high-volume production environment at its Genomic Services Laboratory.
The system will be used for sequencing individuals entire genetic make-up or DNA, and it helps to produce and analyse genomic data on timescales, at a cost relevant to enable routine human whole genome sequencing.
According to the Institute, genomic information is useful for diagnosing and treating diseases, as hospitals and healthcare organisations use genetic testing to determine proper treatment regimens for patients.
HudsonAlpha Institute for Biotechnology president Richard Myers said: "People are inherently curious and concerned about their health and that of their families.
"Most of us wouldn't trade our health for anything, and the HiSeq X Ten sequencing system will help HudsonAlpha continue to produce data that can reveal the genetic causes of inherited diseases and advance our understanding of complex disorders.
"With our organisation's roots in the Human Genome Project, we know intimately how important a deep understanding of technology is to articulating the best scientific questions and interpreting the massive amount of data that sequencing generates."
The Institute also noted the system will help its genomic scientists and educators better communicate how genomic information can be incorporated into patient care and treatment.
HudsonAlpha was recently approved by federal government to accept clinical samples for sequencing and return results directly to physicians, in addition to continuing their research.
Image: The Illumina HiSeq X Ten System. Photo: courtesy of PRNewswire / HudsonAlpha Institute for Biotechnology.